

**Best
Available
Copy**

AD-A286 306

DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0168

Information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Avenue, Suite 1204, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0168), Washington, DC 20503.

2. REPORT DATE 1994		3. REPORT TYPE AND DATES COVERED Journal article																					
4. TITLE AND SUBTITLE Immunology, pathophysiology, and treatment of malaria		5. FUNDING NUMBERS PE - 62787A PR - 001.01 TA - EFX WU - 1432																					
6. AUTHOR(S) Crutcher JM, Jones TR, Hoffman SL		8. PERFORMING ORGANIZATION REPORT NUMBER NMRI 94-59																					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Naval Medical Research Institute Commanding Officer 8901 Wisconsin Avenue Bethesda, Maryland 20889-5607																							
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Naval Medical Research and Development Command National Naval Medical Center Building 1, Tower 12 8901 Wisconsin Avenue Bethesda, Maryland 20889-5606		10. SPONSORING/MONITORING AGENCY REPORT NUMBER DN244532																					
11. SUPPLEMENTARY NOTES Reprinted from: Current Opinion in Infectious Diseases 1994 Vol.7 pp. 529-535																							
12a. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution is unlimited.		12b. DISTRIBUTION CODE																					
13. ABSTRACT (Maximum 200 words)																							
<table border="1"> <tr> <td colspan="2">Accession For</td> </tr> <tr> <td>NTIS CRA&I</td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>DTIC TAB</td> <td><input type="checkbox"/></td> </tr> <tr> <td>Unannounced</td> <td><input type="checkbox"/></td> </tr> <tr> <td colspan="2">Justification</td> </tr> <tr> <td colspan="2">By</td> </tr> <tr> <td colspan="2">Distribution /</td> </tr> <tr> <td colspan="2">Availability Codes</td> </tr> <tr> <td>Dist</td> <td>Avail and/or Special</td> </tr> <tr> <td>A-1</td> <td>20</td> </tr> </table>				Accession For		NTIS CRA&I	<input checked="" type="checkbox"/>	DTIC TAB	<input type="checkbox"/>	Unannounced	<input type="checkbox"/>	Justification		By		Distribution /		Availability Codes		Dist	Avail and/or Special	A-1	20
Accession For																							
NTIS CRA&I	<input checked="" type="checkbox"/>																						
DTIC TAB	<input type="checkbox"/>																						
Unannounced	<input type="checkbox"/>																						
Justification																							
By																							
Distribution /																							
Availability Codes																							
Dist	Avail and/or Special																						
A-1	20																						
14. SUBJECT TERMS malaria; immunology; therapy; pathophysiology; review; vaccine		15. NUMBER OF PAGES 6																					
		16. PRICE CODE																					
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited																				

Immunology, pathophysiology, and treatment of malaria

James M. Crutcher, Trevor R. Jones and Stephen L. Hoffman

Malaria Program, Naval Medical Research Institute, Rockville, Maryland, USA

Despite increasing research and control efforts over the past 20 years, malaria remains one of the world's most significant health problems. As the disease flourishes and drug resistance spreads, the search for vaccines and effective drugs for therapy and prophylaxis becomes ever more important. Recent advances in our understanding of the ultrastructure and biology of *Plasmodia* will aid that quest. For vaccines, work continues on identifying the immune mechanisms and parasite targets responsible for protective immunity and developing methods of constructing the subunit vaccines that will provide such immunity. One promising vaccine, SPf66, is being evaluated in several field trials. Mefloquine, the drug most commonly used for prophylaxis in areas with chloroquine-resistant *Plasmodium falciparum*, remains effective in most areas, except in parts of southeast Asia where high-grade multidrug resistance is prevalent. In prophylactic doses, it has proved to be as safe as chloroquine. For therapy, halofantrine is highly effective in areas with drug resistance. Artemisinin compounds are effective in treating severe malaria caused by multidrug-resistant *P. falciparum*.

94-35045

8/8

Current Opinion in Infectious Diseases 1994, 7:529-535

Introduction

Primarily a disease of tropical developing countries, malaria is conservatively estimated to cause 200-300 million new cases and 2 million deaths each year, the majority in sub-Saharan Africa. It also poses a significant threat to travelers. Because of increasing drug resistance and deteriorating economic and social conditions in many malaria-endemic countries, many experts expect the situation to get worse.

The organism's complex life cycle further complicates control efforts. Vaccines and drugs may be effective against one stage of the parasite but have little or no effect against other stages. Infection begins when an anopheline mosquito injects *Plasmodium* spp. sporozoites when taking a blood meal. Within minutes sporozoites invade liver cells, where they multiply. Infected human liver cells rupture after a minimum of 5 days and release tens of thousands of merozoites into the circulation, where the merozoites invade red blood cells (RBCs) and multiply again. After 48-72 h the RBC ruptures, releasing six to 30 new merozoites, which invade other RBCs and start the erythrocytic cycle over again. The liver stage of infection is asymptomatic. It is not until the rupture of RBCs that clinical manifestations occur. Ultimately, some merozoites differentiate into the forms that infect the mosquito, male and female gametocytes. When ingested by an anopheline mosquito, these forms result in the formation of sporozoites, which can then be injected into the host when the mosquito takes a blood meal.

Vaccine development

Vaccine strategies may be directed against any of the above stages. Pre-erythrocytic vaccines focus on inducing antibodies against extracellular sporozoites in the bloodstream, and antibodies, T-cell responses, and cytokines to attack the parasite developing within hepatocytes. Erythrocytic (blood stage) vaccines will be designed to induce antibodies that block extracellular merozoite invasion of erythrocytes, and antibodies and cytokines to attack the infected erythrocyte. Transmission-blocking vaccines may induce antibodies or cytokines that attack gametocytes within erythrocytes, or antibodies that prevent development of the extracellular stages within mosquitoes. A final approach is to limit disease by preventing the release from infected erythrocytes of parasite material that induces the human host to produce cellular products (including cytokines) thought to be important in pathogenesis. It is almost certain that an effective vaccine will have to be multivalent, attacking several parasite stages.

Immunization with irradiated sporozoites induces sterile immunity in humans and laboratory animals, providing the basis for efforts to develop pre-erythrocytic vaccines. Since irradiated sporozoites are not a practical means of immunization, subsequent research has focused on identifying the immune mechanisms and parasite proteins responsible for this protection and producing subunit vaccines. So far subunit vaccines have not proven as efficacious as irradiated sporozoites. Several recent studies

Abbreviations

CSP—circumsporozoite protein; RBC—red blood cell.

have shed light on irradiated sporozoite-induced immunity. Egan *et al.* [1*] demonstrated for the first time that immunization with irradiated sporozoites induces antibodies against regions of the circumsporozoite protein (CSP; the major sporozoite surface protein) outside the immunodominant central repeat region. These nonrepeating (flanking) regions could account for part of the protection resulting from irradiated sporozoites immunization. Rodrigues *et al.* [2*] showed that irradiated sporozoite-induced antibodies alone reduced liver parasites in mice by 47% and that CD4⁺ and CD8⁺ T cells each had strong (and similar) antiparasitic effects. Weiss *et al.* [3**] showed that CD4⁺ T cells were required for protective immunization with irradiated sporozoites, apparently because of their helper functions and not as direct effector cells. By immunizing with a vaccinia virus expressing the *Plasmodium yoelii* CSP and a recombinant influenza virus expressing a *P. yoelii* CSP CD8⁺ T-cell epitope, Li *et al.* [4*] were able to protect 60% of mice; the protection was dependent on CD8⁺ T cells. These studies reinforce the notion that antibodies, CD4⁺ T cells, and CD8⁺ T cells against pre-erythrocytic stages can all be protective independently.

Until now, the longest duration of irradiated sporozoite-induced immunity has been 56 days. Edelman *et al.* [5**] reported a trial in which a patient immunized with irradiated sporozoites was protected when challenged 9 months after his last immunization.

The role of lymphocytes expressing the $\gamma\delta$ T-cell receptor in immunity to malaria was investigated by Tsuji *et al.* [6*]. They found that irradiated sporozoite immunization of $\alpha\beta$ T cell-deficient mice induced an immune response that significantly inhibited development of liver stage parasites, suggesting $\gamma\delta$ T cells may play a role in liver stage immunity.

Identification of specific protective parasite epitopes may be important for subunit vaccine design. Moreno *et al.* [7*] identified a 20 amino acid epitope from the *P. falciparum* CSP that was recognized by CD4⁺ T-cell clones obtained from irradiated sporozoite-immunized volunteers. Most clones recognized variant peptides from different *P. falciparum* strains, suggesting that polymorphism should not be a serious obstacle to inclusion of this epitope in a subunit vaccine. Malik *et al.* [8*] showed that mice immunized with a recombinant *P. falciparum* CSP produced CD8⁺ T cell-dependent cytolytic activity against a 23 amino acid epitope on the CSP. Importantly, adjuvant was not required for this response.

Working in Thailand, Brown *et al.* [9*] studied the safety, immunogenicity, and protective efficacy in humans of R32Tox-A, a recombinant protein derived from the central repeat region of the *P. falciparum* CSP conjugated to toxin A of *Pseudomonas aeruginosa*. Although it was safe and immunogenic, there was no evidence of efficacy despite induction of extremely high levels of antibodies in some volunteers.

Multiple antigen peptide vaccines are synthetic polymers containing multiple B- and T-cell epitopes. Sev-

eral years ago a multiple antigen peptide vaccine based on the *Plasmodium berghei* CSP repeat region was shown to protect up to 80% of mice against sporozoite challenge [10]. Calvo-Calle *et al.* [11*] characterized the immune response in mice to multiple antigen peptides containing the immunodominant B-cell epitope (NANP)₃ and various T-helper epitopes from the *P. falciparum* CSP. The level of response depended on the sequence and stoichiometry of the multiple antigen peptide, and the strain of mice. One of the multiple antigen peptide constructs significantly boosted the anti-sporozoite antibody response in mice immunized with irradiated sporozoites. This opens the possibility of using multiple antigen peptide vaccines to boost immune responses of people living in malaria-endemic areas.

Several blood stage parasite antigens are under investigation. Su *et al.* [12*] reported on the mechanism whereby the major merozoite surface protein-1 binds to erythrocytes. Daly and Long [13**] and Ling *et al.* [14**] reported for the first time that a fragment of merozoite surface protein-1 from *P. yoelii* induced protective immunity in mice. Serine repeat antigen is a *P. falciparum* protein expressed by both liver and blood stage parasites. Tine *et al.* [15*] reported that a recombinant vaccinia virus expressing a serine repeat antigen DNA fragment produced anti-serine repeat antigen antibodies in rabbits and Inselburg *et al.* [16**] demonstrated reduction in parasitemia in *Aotus* monkeys immunized with a serine repeat antigen peptide.

For transmission blocking vaccines, it was demonstrated that antibodies against the mosquito midgut [17*] and the gametocyte protein Pf52400 [18*] inhibited parasite development in the mosquito.

SPf66 is a synthetic malaria vaccine containing three peptides of merozoite origin and one from the CSP of *P. falciparum*. Valero *et al.* [19**] described 1548 volunteers of all ages, half of whom received the vaccine. SPf66 was safe and immunogenic and had a protective efficacy of 39% against *P. falciparum* (34% against first infection). It was most effective in children under 5 years of age and adults over 45 years of age.

Chemotherapy, prophylaxis, and drug resistance

Chloroquine-resistant *P. falciparum* is present in most malarious areas of the world. Resistance to other drugs is common in many areas. Chloroquine-resistant *P. vivax* is now present in Papua New Guinea [20] and Indonesia [21]. This widespread resistance, often to multiple drugs, complicates therapy and chemoprophylaxis of malaria and underscores the need for new and effective drugs.

Since chloroquine is an ideal drug (inexpensive, effective, and well tolerated) in areas where resistance has not developed, work is ongoing to determine the mechanism of chloroquine resistance in an attempt to reverse it [22*].

At present, however, success has been limited and other drugs, generally with greater toxicity, must be used.

Mefloquine is widely used for malaria therapy and prophylaxis. Although highly effective against chloroquine-resistant *P. falciparum* in most areas, there have been concerns about side effects, especially involving the central nervous system. Several recent studies have shown prophylactic doses to be as safe as chloroquine [23[•],24[•],25[•]]. Boudreau *et al.* [23[•]] found that mefloquine caused mild sleep disturbance, increased dream activity, and feelings of depression, which generally decreased over time. Another important issue concerns effective blood levels. In West Africa, Lobel *et al.* [24[•]] suggested that 95% prophylactic efficacy is achieved at whole blood mefloquine concentrations of about 620 ng/ml. Boudreau *et al.* [23[•]] found that protective trough plasma mefloquine concentrations (500–600 ng/ml) were not achieved with 250 mg mefloquine a week until 7 weeks after starting prophylaxis. When a 3-day loading dose (250 mg/day) was used, the mean level was 665 ng/ml after 72 h. The authors suggested a loading dose be considered for short-term adult travelers to areas with chloroquine-resistant *P. falciparum*. Mefloquine resistance has been reported from many areas and is prevalent in some areas of southeast Asia. For therapy, 15 mg/kg suffices in areas where organisms remain sensitive to mefloquine, but for resistant organisms 25 mg/kg is needed. In areas of high-level mefloquine resistance the addition of oral artesunate has proven highly effective [26[•]]. Fortunately, most mefloquine treatment failures respond to quinine and doxycycline [27[•]].

Halofantrine is another drug for therapy of chloroquine-resistant *P. falciparum* infections. Although 24 mg/kg (in three doses at 8-h intervals) is effective for sensitive strains, higher doses are needed for resistant strains and for use in nonimmune patients [28]. In areas of highly drug-resistant malaria in Thailand, high-dose halofantrine was found to be highly effective and better tolerated than both mefloquine and quinine plus doxycycline [29[•],30[•]]. It was especially effective for retreatment of mefloquine failures [29[•]]. When used in higher doses, however, it caused dose-related lengthening of PR and QT intervals in all of 61 patients studied [31[•]]. This arrhythmogenic potential should be considered when using halofantrine.

Artemisinin compounds (qinghaosu) are very promising for the treatment of chloroquine-resistant *P. falciparum*; they decrease parasitemia faster than all other antimalarial drugs with no apparent toxicity [32[•]]. Unfortunately, when compared with quinine for treating patients with cerebral malaria caused by quinine-sensitive parasites, artemisinin compounds have not been shown to reduce mortality. They do, however, decrease the time until the patient regains consciousness [33[•]]. In a study of Rhesus monkeys infected with *Plasmodium coatneyi*, Maeno *et al.* [34[•]] showed for the first time, *in vivo*, that arte-

sunate reduced the rate of parasitized RBC sequestration in cerebral microvessels.

Since anopheline mosquitoes feed at night, bed nets are an important component of malaria prevention efforts. In the Gambia, West Africa [35[•]], permethrin-impregnated bed nets were cost-effective and provided significant protection from mortality, morbidity, and infection in children aged 6 months to 5 years.

Clinical aspects

The pathophysiology of cerebral malaria, the most severe complication of falciparum malaria, is an area of intense research interest. Cerebral malaria is associated with sequestration of parasitized RBCs in the brain microvasculature. Current evidence [36[•]] suggests this phenomenon results from a combination of rosetting (binding of uninfected RBCs and parasitized RBCs) and cytoadherence (adhesion of parasitized RBCs to vascular epithelium). Studies are attempting to define the receptors on the RBC and vascular epithelium as well as the cytokine mediators responsible for this binding. Crandall *et al.* [37[•]] found that two synthetic peptides based on motifs from band 3 protein of human parasitized RBCs inhibited adhesion of *P. falciparum*-infected RBCs *in vitro* and affected sequestration in *Aotus* and *Saimiri* monkeys. Further, monoclonal antibodies against these RBC proteins block cytoadherence. This has important implications for the treatment of cerebral malaria.

Cytokines have been implicated in the pathogenesis of malaria. Tumor necrosis factor, for example, has been associated with severe malaria. Kwiatkowski *et al.* [38[•]] used a murine monoclonal antibody to neutralize tumor necrosis factor in Gambian children with cerebral malaria. Although the therapy did reduce fever, it did not affect mortality.

Malaria is usually diagnosed by observing parasites in Giemsa-stained blood smears. Sensitive diagnosis requires expert interpretation and is time-consuming. Several new methodologies are under investigation, including polymerase chain reaction/DNA probe techniques [39[•]], determination of parasite lactate dehydrogenase in patient serum [40[•]], and a rapid dipstick antigen-capture assay for *P. falciparum* [41[•]]. The dipstick holds special promise because of its ease, speed of use, and high sensitivity and specificity.

General biology

Of particular note in the past year was the discovery by Goonewardene *et al.* [42[•]] of a method for the introduction and transient expression of a foreign gene in a malaria parasite. The ability to transfect malaria parasites with DNA and thereby study the function of malaria

genes will open the way to a better understanding of the basic biology of the parasite. Further work is required to establish methods for the stable transfection of *Plasmodium* parasites.

Plasmodium parasites

Host hemoglobin is a major energy source for intra-erythrocytic *Plasmodium*. Interfering with hemoglobin catabolism is toxic to the parasite. Gluzman *et al.* [43*] reported the isolation and characterization of three proteases that account for the majority of hemoglobin-degrading activity. The proteases were shown to work in an ordered manner, synergistically, and with distinct specificities. This knowledge makes possible the development of drugs that interfere with this essential catabolic pathway.

Antigenic polymorphism is a concern in vaccine development, especially for a complex organism such as *Plasmodium*. If antigenic properties change rapidly then vaccines may only work for a short time. Qari *et al.* [44*] compared present-day CSPs of *P. falciparum*, *P. vivax*, and *P. malariae* with that of organisms collected over the past 50 years and found limited polymorphism. They concluded that such minimal changes should not undermine the use of the CSP as a vaccine antigen.

Other works of interest

A book with nine excellent reviews of molecular immunological considerations in malaria vaccine development [45**] and a review article describing current knowledge of T-cell responses to pre-erythrocytic stages of malaria [46**] were published in 1993.

Conclusion

During the past year there have been a number of extremely important advances that point the way to future work to control malaria. The report from Colombia [19**] that SPf66 provided partial protection in field studies has led to enormous enthusiasm for this vaccine. Studies in progress in Africa, Asia, and South America should establish whether this vaccine is protective in a variety of epidemiologic settings. The report by Daly and Long [13**] and Ling *et al.* [14**] that immunization with purified recombinant *P. yoelii* merozoite surface protein-1 protects mice will undoubtedly provide the foundation for similar studies in humans, and the report by Inselburg *et al.* [16**] showing protection of monkeys with purified recombinant serine repeat antigen should also lead to human trials. Such efforts pro-

vide some of the components for the multicomponent malaria vaccines that most investigators think will be required for effective protection against these parasites.

The major advances in treatment have been to continue to show that artemether and other artemisinin compounds are at least as effective as quinine for treating severe malaria and will probably be as effective in treating quinine-resistant parasites. The work of Crandall *et al.* [37**] demonstrating that band 3 peptides inhibit cytoadherence has the potential to provide a new treatment for severe malaria after extensive additional testing. Because of the rapidity of development of resistance to all antimalarials, and the continued high mortality rates in patients with severe malaria, the development of new antimalarials and adjunct therapies to reduce mortality of severe malaria is still critical.

The finding by Beadle *et al.* [41**] that a dipstick is highly sensitive and specific for diagnosis of *P. falciparum* may revolutionize diagnosis of malaria, particularly by inexperienced technicians in areas where malaria is not transmitted. A similar assay for *P. vivax* must now be developed.

Finally, the demonstration by Goonewardene *et al.* [42**] of transient transfection of *Plasmodium gallinaceum* gametes provides the first step towards an enormously important goal of malariologists: stable transfection of *Plasmodium* spp. The ability to transfect stably the parasite will revolutionize study of these parasites and must be a major focus of current work.

Acknowledgement

This work was supported by Naval Medical Research and Development Command work units 611102A.s13.00101.BFX.1431.612787A.870.00101.EFX.1432 and 623002A.810.00101.HFX.1433. The opinions and assertions herein are those of the authors and are not to be construed as official or as reflecting the views of the US Navy or the naval services at large.

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Egan JE, Hoffman SL, Haynes JD, Sadoff JC, Schneider I, Grau GE, Hollingdale MR, Ballou WR, Gordon DM: Humoral Immune Responses in Volunteers Immunized With Irradiated *Plasmodium falciparum* Sporozoites. *Am J Trop Med Hyg* 1992, 49:166-173.

After immunization with irradiated sporozoites, three out of four vaccinees were protected against challenge with the homologous *P. falciparum* strain and two out of two were protected against a heterologous strain.

2. Rodrigues M, Nussenzweig RS, Zavala F: The Relative Contribution of Antibodies, CD4⁺ and CD8⁺ T Cells to Sporozoite Induced Protection Against Malaria. *Immunology* 1993, 80:1-5.

The contribution of antibodies and CD4⁺ and CD8⁺ T cells to sporozoite-induced protection was quantitated by measurement of plasmodial ribosomal RNA in the liver of sporozoite-challenged mice.

3. Weiss WR, Sedegah M, Berzofsky JA, Hoffman SL: The Role of CD4⁺ T Cells in Immunity to Malaria Sporozoites. *J Immunol* 1993, 151:2690-2698.

Mice treated with anti-CD4⁺ antibody before immunization with irradiated sporozoites were susceptible to infection, whereas the same treatment after immunization depleted CD4⁺ cells to the same degree but left immunity intact. Depletion of CD4⁺ cells reduced help for both B- and T-cell effector functions.

4. Li S, Rodrigues M, Rodriguez D, Rodriguez JR, Esteban M, Palese P, Nussenzweig RS, Zavala F: Priming with Recombinant Influenza Virus Followed by Administration of Recombinant Vaccinia Virus Induces CD8⁺ T-Cell-Mediated Protective Immunity Against Malaria. *Proc Natl Acad Sci USA* 1993, 90:5214-5218.

Administration of influenza virus expressing a CD8⁺ T-cell epitope from the CSP of *P. yoelii* followed by vaccinia virus expressing the entire CSP induced protective immunity against sporozoite challenge. The sequence of immunization appears crucial as reversing the order failed to induce protection.

5. Edelman R, Hoffman SL, Davis JR, Beier M, Szein MB, Losonsky G, Herrington DA, Eddy HA, Hollingdale MR, Gordon DM, et al.: Long-Term Persistence of Sterile Immunity in a Volunteer Immunized with X-Irradiated *Plasmodium falciparum* Sporozoites. *J Infect Dis* 1993, 168:1066-1070.

Immunoglobulin G antibody response to two related circumsporozoite antigens (R32LR and NANP₅₀) increased progressively during the primary series. There was an unexplained rapid fall in R32LR after the first malaria challenge. The booster series 3 months later was followed by a rapid rise in immunoglobulin G antibody and a subsequent slow decay over 12 months.

6. Tsuji M, Mombaerts P, Lefrançois L, Nussenzweig RS, Zavala F, Tonegawa S: $\gamma\delta$ T Cells Contribute to Immunity Against the Liver Stages of Malaria in $\alpha\beta$ T-Cell-Deficient Mice. *Proc Natl Acad Sci USA* 1994, 91:345-349.

The role of $\gamma\delta$ T cells in immunity to liver stage malaria infection was determined by measuring parasite ribosomal RNA in $\alpha\beta$ T cell-deficient mice immunized with irradiated sporozoites.

7. Moreno A, Clavijo P, Edelman R, Davis J, Szein M, Sinigaglia F, Nardin E: CD4⁺ T Cell Clones Obtained from *Plasmodium falciparum* Sporozoite-Immunized Volunteers Recognize Polymorphic Sequences of the Circumsporozoite Protein. *J Immunol* 1993, 151:489-499.

The 20 amino acid epitope P1 Th/Tc contains part of the highly conserved region II, as well as part of a polymorphic domain of the *P. falciparum* CSP.

8. Malik A, Cross M, Ulrich T, Hoffman SL: Induction of Cytotoxic T Lymphocytes Against the *Plasmodium falciparum* Circumsporozoite Protein by Immunization with Soluble Recombinant Protein without Adjuvant. *Infect Immun* 1993, 61:5062-5066.

The epitope of study (RLF) was the entire CSP of the 7G8 clone of *P. falciparum* minus the 164 amino acids that constitute the central repeat region. This was fused to 81 amino acids from the nonstructural protein of influenza A and tested for cytotoxic T-lymphocyte activity with and without the adjuvant DETOX.

9. Brown AE, Singharaj P, Webster HK, Pipithkul J, Gordon DM, Boslego JW, Krinchai K, Su-Archawaratana P, Wongsrichanalai C, Ballou WR, et al.: Safety, Immunogenicity and Limited Efficacy Study of a Recombinant *Plasmodium falciparum* Circumsporozoite Vaccine in Thai Soldiers. *Vaccine* 1994, 12:102-108.

A randomized, double-blind study of 199 Thai soldiers who received either R32Tox-A or control vaccine at 0, 8, and 16 weeks.

10. Tam JP, Clavijo P, Lu Y-A, Nussenzweig V, Nussenzweig RS, Zavala F: Incorporation of T and B Epitopes of the Circumsporozoite Protein in a Chemically Defined Synthetic Vaccine Against Malaria. *J Exp Med* 1990, 171:299-306.

11. Calvo-Calle JM, De Oliveira GA, Clavijo P, Maracic M, Tam JP, Lu Y-A, Nardin EH, Nussenzweig RS, Cochrane AH: Immunogenicity of Multiple Antigen Peptides Containing B and Non-Repeat T Cell Epitopes of the Circumsporozoite Protein of *Plasmodium falciparum*. *J Immunol* 1993, 150:1403-1412.

Findings suggested that only a small proportion of the antibodies elicited by the tested multiple antigen peptides reacted with native CSP.

12. Su S, Sanadi AR, Ifon E, Davidson EA: A Monoclonal Antibody Capable of Blocking the Binding of PF200 (MSA-1) to Human Erythrocytes and Inhibiting the Invasion of Merozoites into Human Erythrocytes. *J Immunol* 1993, 151:2309-2317.

Glycophorin A is an important receptor on the erythrocyte membrane for *P. falciparum* merozoites. Using a bank of monoclonal antibodies, the authors localized the merozoite binding region on glycophorin A to the 31 residues at the amino terminal.

13. Daly TM, Long CA: A Recombinant 15-Kilodalton Carboxyl-Terminal Fragment of *Plasmodium yoelii* 17XL Merozoite Surface Protein 1 Induces a Protective Immune Response in Mice. *Infect Immun* 1993, 61:2462-2467.

An *Escherichia coli*-produced fragment of merozoite surface protein-1, an important malaria vaccine candidate, successfully protected mice from challenge with *P. yoelii*. The region is highly conserved among isolates, suggesting that immunity to it would not be strain-specific.

14. Ling IT, Ogun SA, Holder AA: Immunization Against Malaria with a Recombinant Protein. *Parasit Immunol* 1994, 16:63-67.

The *E. coli*-produced carboxy-terminal domain of *P. yoelii* merozoite surface protein-1 was highly protective against sporozoite challenge infection in mice. Protein conformation was critically important as protection was lost when the disulfide bonds of the protein were disrupted.

15. Tine JA, Conseil V, Delplace P, De Taisne C, Camus D, Paoletti E: Immunogenicity of the *Plasmodium falciparum* Serine Repeat Antigen (p126) Expressed by Vaccinia Virus. *Infect Immun* 1993, 61:3933-3941.

The gene for serine repeat antigen, a blood and liver stage *P. falciparum* antigen, was inserted in a vaccinia virus. The recombinant virus induced antibodies in rabbits that recognized native serine repeat antigen.

16. Inselburg J, Bathurst IC, Kansopan J, Barr PJ, Rossan R: Protective Immunity Induced in Aotus Monkeys by a Recombinant SERA Protein of *Plasmodium falciparum*: Further Studies Using SERA 1 and MF75.2 Adjuvant. *Infect Immun* 1993, 61:2048-2052.

Immunization with a fragment of serine repeat antigen induced measurable levels of protection to blood stage parasite challenge.

17. Lal AA, Schrieffer ME, Sacchi JB, Goldman IF, Louis-Wileman V, Collins WE, Azad AF: Inhibition of Malaria Parasite Development in Mosquitoes by Anti-Mosquito-Midgut Antibodies. *Infect Immun* 1994, 62:316-318.

Mice were immunized with a preparation of the midguts of mosquitoes infected with *P. berghei*. Mosquitoes fed on these mice had a reduced number of oocysts and sporozoite-positive salivary glands.

18. Feng Z, Hoffmann RN, Nussenzweig RS, Tsuji M, Fujioka H, Aikawa M, Lensen THW, Onnudurai T, Pologé LG: Pfs2400 Can Mediate Antibody-Dependent Malaria Transmission Inhibition and May Be The *Plasmodium falciparum* 11.1 Gene Product. *J Exp Med* 1993, 177:273-281.

Monoclonal antibody to a component of the parasitophorous vacuole inhibited oocyst formation in mosquitoes fed on blood containing the antibody.

19. Valero MV, Amador LR, Galindo C, Figueroa J, Bello MS, Murillo LA, Mora AL, Patarroyo G, Rocha CL, Rojas M, et al.: Vaccination with SPf66, a Chemically Synthesized Vaccine, against *Plasmodium falciparum* malaria in Colombia. *Lancet* 1993, 341:705-710.

A multivalent vaccine containing merozoite and sporozoite sequences was tested in 738 volunteers. It was safe, immunogenic, and induced an overall protection rate of 33% for first episodes and was most effective at protecting children under 5 years of age.

20. Rieckmann KH, Davis DR, Hutton DC: *Plasmodium vivax* Resistance to Chloroquine? *Lancet* 1989, ii:1183-1184.

21. Murphy GS, Basri H, Purnomo, Andersen EA, Bangs MJ, Mount DL, Gorden J, Lal AA, Purwokusumo AR, Harjosuwarno S, et al.: Vivax Malaria Resistant to Treatment and Prophylaxis with Chloroquine. *Lancet* 1993, 341:96-100.

22. Slater AFG: Chloroquine: Mechanism of Drug Action and Resistance in *Plasmodium falciparum*. *Pharmacol Ther* 1993, 57:203-235.

A comprehensive review of the mechanism of action and resistance to chloroquine.

23. Boudreau E, Schuster B, Sanchez J, Novakowski W, Johnson R, Redmond D, Hanson R, Dausel L: Tolerability of Prophylactic Larium Regimens. *Trop Med Parasitol* 1993, 44:257-265.
A study of side effects of two prophylactic regimens of mefloquine (250 mg weekly, or 250 mg daily for 3 days followed by 250 mg weekly) compared with chloroquine (300 mg weekly) in a randomized, double-blind study of 359 US Marines.
24. Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell CC: Long-Term Malaria Prophylaxis with Weekly Mefloquine. *Lancet* 1993, 341:848-851.
Study of US Peace Corps volunteers in West Africa found weekly mefloquine to be significantly more effective than weekly chloroquine, weekly chloroquine plus daily proguanil, and every other week mefloquine. No serious adverse effects were noted and the frequency of mild adverse effects was similar in the mefloquine and chloroquine groups.
25. Steffen R, Fuchs E, Schildknecht J, Naef U, Funk M, Schlagenhauf P, Phillips-Howard P, Nevill C, Sturchler D: Mefloquine Compared with Other Chemoprophylactic Regimens in Tourists Visiting East Africa. *Lancet* 1993, 341:1299-1303.
A retrospective study of 145 000 European travelers to East Africa found mefloquine to have a prophylactic effectiveness of 91%, which was significantly greater than chloroquine plus proguanil (72%), and to have similar tolerance to that of chloroquine alone.
26. White NJ: Mefloquine: In the Treatment and Prophylaxis of *Falciparum* Malaria. *BMJ* 1994, 308:286-287.
A brief review of the current status of mefloquine use.
27. Fontanet AL, Johnston BD, Walker AM, Rooney W, Thimasarn K, Sturchler D, MacDonald M, Hours M, Wirth DF: High Prevalence of Mefloquine-Resistant Malaria in Eastern Thailand. *Bull World Health Organ* 1993, 71:377-383.
A study of 113 patients in eastern Thailand with uncomplicated malaria treated with a single dose of 15 mg/kg mefloquine found a failure rate of 59%. Of those who failed mefloquine, 95% responded to quinine plus doxycycline.
28. Weinke T, Loscher T, Fleischer K, Kretschmer H, Pohle HD, Kohler B, Schlunk T, Clemens R, Bock HL: The Efficacy of Halofantrine in the Treatment of Acute Malaria in Nonimmune Travelers. *Am J Trop Med Hyg* 1992, 47:1-5.
29. ter Kuile FO, Dolan G, Nosten F, Edstein MD, Luxemburger C, Phaipun L, Chongsuphajaisiddhi T, Webster HK, White NJ: Halofantrine Versus Mefloquine in Treatment of Multidrug-Resistant *Falciparum* Malaria. *Lancet* 1993, 341:1044-1049.
Halofantrine at 24 mg/kg/day (in three doses at 8-h intervals) for 3 days was more effective than mefloquine at 25 mg/kg (failure rates of three and 8%, respectively), and better tolerated, for therapy of uncomplicated *falciparum* malaria in a multidrug-resistant area in western Thailand.
30. Watt G, Loesutiviboon L, Jongsakul K, Shanks GD, Ohrt CK, Kamasuta C, Schuster B, Fleckenstein L: Efficacy and Tolerance of Extended-Dose Halofantrine for Drug-Resistant *Falciparum* Malaria in Thailand. *Am J Trop Med Hyg* 1994, 50:187-192.
Halofantrine at 500 mg every 4 h on the first day, followed by 500 mg/day for 6 days, was as efficacious as quinine plus doxycycline for 7 days (cure rates of 92 and 85%, respectively), and better tolerated, for therapy of uncomplicated *falciparum* malaria in a multidrug-resistant area in eastern Thailand.
31. Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, White NJ: Cardiac Effects of Antimalarial Treatment With Halofantrine. *Lancet* 1993, 341:1054-1056.
In a prospective electrocardiographic study in Thailand, mefloquine (25 mg/kg) had no cardiac effects, but halofantrine (72 mg/kg) induced dose-related lengthening of PR and QT intervals in all 61 patients studied. Significant QT prolongation was more likely when halofantrine was used as retreatment for mefloquine failures.
32. Hien TT, White NJ: Qinghaosu. *Lancet* 1993, 341:603-608.
A review of the history, pharmacology, and clinical studies of quinghaosu (artemisinin) and its derivatives.
33. Taylor TE, Wills BA, Kazembe P, Chisale M, Wirima JJ, Ratsma EY, Molyneux ME: Rapid Coma Resolution with Artemether in Malawian Children with Cerebral Malaria. *Lancet* 1993, 341:661-662.
Coma resolution times were shorter with artemether than with quinine [8 (4-15) and 14 (10-36) h, respectively, $P=0.01$].
34. Maeno Y, Brown AE, Smith CD, Tegoshi T, Toyoshima T, Ockenhouse CF, Corcoran KD, Ngampochjana M, Kyle DE, Webster HK, et al.: A Nonhuman Primate Model for Human Cerebral Malaria: Effects of Artesunate (Quinghaosu Derivative) on Rhesus Monkeys Experimentally Infected With *Plasmodium coatneyi*. *Am J Trop Med Hyg* 1993, 49:726-734.
The percentage of cerebral microvessels with sequestered parasitized RBCs was 29.4% in controls and 0-2% in artesunate-treated animals.
35. Greenwood BM, Baker JR (Eds): A Malaria Control Trial Using Insecticide-Treated Bed Nets and Targeted Chemoprophylaxis in a Rural Area of The Gambia, West Africa. *Trans R Soc Trop Med Hyg* 1993, 87(suppl 2):1-60.
A comprehensive review of design, implementation, and results of trial to determine effectiveness of bed nets and chemoprophylaxis on malaria morbidity and mortality in an endemic area in West Africa.
36. Wahlgren M, Fernandez V, Scholander C, Carlson J: Rosetting. *Parasitol Today* 1994, 10:73-79.
A review of the mechanisms of rosette formation and cytoadherence and potential intervention strategies.
37. Crandall I, Collins WE, Gysin J, Sherman IR: Synthetic Peptides Based on Motifs Present in Human Band 3 Protein Inhibit Cytoadherence/Sequestration of the Malaria Parasite *Plasmodium falciparum*. *Proc Natl Acad Sci USA* 1993, 90:4703-4707.
The peptides blocked in a dose-dependent fashion the in-vitro adherence of *P. falciparum*-infected RBCs to C32 amelanotic melanoma cells. Intravenous infusion of these peptides into Aotus and Saimiri monkeys infected with sequestering isolates of *P. falciparum* resulted in the appearance of mature forms of the parasite in the peripheral circulation, suggesting they were being freed from vasculature endothelium by competition of peptides for binding sites.
38. Kwiatkowski D, Molyneux ME, Curtis SN, Klein N, Pointaire P, Smit M, Brewster DR, Grau GE, Greenwood BM: Anti-TNF Therapy Inhibits Fever in Cerebral Malaria. *Q J Med* 1993, 86:91-98.
Monoclonal antibody-mediated tumor necrosis factor therapy reduced fever in cerebral malaria patients.
39. Laserson KF, Petralanda I, Hamlin DM, Almera R, Fuentes M, Carrasquel A, Barker RH: Use of the Polymerase Chain Reaction to Directly Detect Malaria Parasites in Blood Samples From the Venezuelan Amazon. *Am J Trop Med Hyg* 1994, 50:169-180.
A study of 229 blood samples from 48 patients found the DNA probe/polymerase chain reaction method to have a sensitivity of 78%, a specificity of 97%, a positive predictive value of 88%, and to be highly reproducible. It was felt to be most useful for large-scale, field-based epidemiological studies.
40. Makler MT, Hinrichs DJ: Measurement of Lactate Dehydrogenase Activity of *Plasmodium falciparum* as an Assessment of Parasitemia. *Am J Trop Med Hyg* 1993, 48:205-210.
The authors found a correlation between level of parasitemia and an enzyme assay for parasite lactate dehydrogenase activity and suggest this assay may be developed into a simple test for detection of malaria infection.
41. Beadle C, Long GW, Weiss WR, McElroy PD, Maret SM, Oloo AJ, Hoffman SL: Diagnosis of Malaria by Detection of *Plasmodium falciparum* HRP-2 Antigen With a Rapid Dipstick Antigen-Capture Assay. *Lancet* 1994, 343:564-568.
Sensitivity was 96.5-100.0% for detection of *P. falciparum* asexual stages when the parasitemia was greater than 60/ μ l.
42. Goonewardene R, Daily J, Kaslow D, Sullivan TJ, Duffy P, Carter R, Mendis K, Wirth D: Transfection of the Malaria Parasite and Expression of Firefly Luciferase. *Proc Natl Acad Sci USA* 1993, 90:5234-5236.
Plasmid DNA carrying firefly luciferase gene was introduced into *P. gallinaceum* gametes and fertilized zygotes by electroporation. Luciferase activity was detected in parasites electroporated in the presence of the plasmid carrying the luciferase gene but not in controls without the luciferase gene or in parasites not electroporated.
43. Gluzman IY, Francis SE, Oksman A, Smith CE, Duffin KL, Goldberg DE: Order and Specificity of the *Plasmodium falciparum* Hemoglobin Degradation Pathway. *J Clin Invest* 1994, 93:1602-1608.
Aspartic hemoglobinase I acted first to cleave native hemoglobin at the hinge region, unraveling the molecule. Aspartic hemoglobinase II had

some activity on the native hemoglobin, but preferred the denatured molecule. Cysteine protease worked last, recognizing only the denatured molecule.

44. Qari SH, Collins WE, Lobel HO, Taylor F, Lal AA: A Study of Polymorphism in the Circumsporozoite Protein of Human Malaria Parasites. *Am J Trop Med Hyg* 1994, 50:45-51.

In the region of the *P. falciparum* CSP that harbors a T-cell proliferative region and putative hepatocyte binding site (Th1R-N1), 75% of Papua New Guinean and Brazilian isolates had the same sequence as that of a Brazilian 7G8 strain collected in 1980. Other clones showed single amino acid changes.

45. Good MF, Saul AJ (Eds): *Molecular Immunological Considerations in Malaria Vaccine Development*. Boca Raton: CRC Press; 1993.

A review of the advances in basic malaria immunology and issues of malaria vaccine development.

46. Nardin EH, Nussenzweig RS: T Cell Responses to Pre-Erythrocytic Stages of Malaria: Role in Protection and Vaccine Development Against Pre-Erythrocytic Stages. In *Annual Review of Immunology*. Edited by Paul WE, Fathman CG, Metzger H. Palo Alto: Annual Reviews Inc; 1993:687-727.

A review of advances in knowledge of cell-mediated immune mechanisms against malaria parasites, their role in protection, and their relation to malaria vaccine development.

James M. Crutcher, Trevor R. Jones and Stephen L. Hoffman, Malaria Program, Naval Medical Research Institute, 12300 Washington Avenue, Rockville, MD 20852, USA.